Navigation Links
Vion Pharmaceuticals to Present Clinical Data on Cloretazine(R) (VNP40101M) at the ASCO(R) Annual Meeting
Date:5/30/2008

NEW HAVEN, Conn., May 30 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: VION) today announced that data from two clinical trials of its lead anticancer agent Cloretazine(R) (VNP40101M) in acute myelogenous leukemia (AML) would be presented in posters at the 2008 American Society of Clinical Oncology (ASCO(R)) Annual Meeting in Chicago, Illinois.

The poster (Abstract #7051) entitled "A double blind placebo-controlled randomized phase III study of high-dose continuous infusion cytosine arabinoside (araC) with or without VNP40101M in patients with first relapse of AML" will be presented at McCormick Place, South Hall A1, Board 38E from 8:00 a.m. to 12:00 p.m. on Saturday, May 31, 2008. A copy of the poster will be available on Vion Pharmaceuticals' website, http://www.vionpharm.com, on May 31, 2008 at 7:00 a.m. Eastern Time.

The poster (Abstract #7025) entitled "A phase II study of VNP40101M in elderly patients with de novo poor risk AML" will be presented at McCormick Place, Room E450a, Board 15 from 2:00 p.m. to 6:00 p.m. on Monday June 2, 2008. A poster discussion will take place at 5:30 p.m. in Room E354a. A copy of the poster will be available on Vion Pharmaceuticals' website, http://www.vionpharm.com, on June 2, 2008 at 1:00 p.m. Eastern Time.

About Vion

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a si
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine technology :

1. Strativa Pharmaceuticals Announces Preliminary Results from ONCONASE(R) Phase IIIb Clinical Trial
2. Access Pharmaceuticals Presents Favorable Ovarian Cancer Data and Clinical Update on ProLindac(TM) Development at Prestigious International Symposium
3. Access Pharmaceuticals Presents New Data on the Companys Cobalamin(TM) Technology at an International Polymer Therapeutics Symposium
4. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
5. QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
6. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
7. Tioga Pharmaceuticals Asimadoline Demonstrates Positive Results in a Phase 2b Clinical Trial for the Treatment of Irritable Bowel Syndrome
8. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
9. Memory Pharmaceuticals Highlights Progress with Key Programs at its R&D Day
10. Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute
11. VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... Zargis Medical Corp., a majority-owned subsidiary of Speedus ... from Siemens Corporate Research (NYSE: SI ... its award-winning Zargis Cardioscan(TM) system on Amazon.com, America,s ... Bluetooth®-enabled electronic stethoscope were jointly named Popular ... the Year." Cardioscan is the world,s first ...
(Date:12/14/2009)... Gibraltar Associates, a leading public ... domestic communications and issues management, today announced ... PositiveID Corporation (Nasdaq: PSID ) to ... of record. Gibraltar Associates will conduct media ... the Company on its public relations programs. ...
(Date:12/14/2009)... GeoInvesting.com, we have been tracking Tianyin Pharmaceuticals (NYSE Amex: ... hang up had been with the potential dilution from ... income guidance of $11.3 million represents a 43.0% increase ... million, the increase in shares poses some uncertainty regarding ... the share price and the Treasury method of accounting ...
Breaking Medicine Technology:Zargis Cardioscan 'The Intelligent Stethoscope' Now Available on Amazon.com 2Gibraltar Associates Named Agency of Record for Health Information and Diagnostic Provider PositiveID Corporation 2GeoInvesting.com Offers Insight Into Two Growing Chinese Pharmaceutical Firms 2Morehead Presents Webinar on 26apos 3BHe Said 26amp 3B 238230 3BShe Said 3A How Gender Differences Impact Physician Engagement 26apos 3B 55447 1Morehead Presents Webinar on 26apos 3BHe Said 26amp 3B 238230 3BShe Said 3A How Gender Differences Impact Physician Engagement 26apos 3B 55447 2Slogan Contest Educates Young Baseball and Softball Players About the Dangers of Tobacco Use 55445 1Slogan Contest Educates Young Baseball and Softball Players About the Dangers of Tobacco Use 55445 2MN Community Measurement Brings Cost and Quality Information Together For Consumers 55443 1MN Community Measurement Brings Cost and Quality Information Together For Consumers 55443 2MN Community Measurement Brings Cost and Quality Information Together For Consumers 55443 3
(Date:12/14/2009)... variants seen in one gene, researchers say , , MONDAY, ... a dozen genetic variants in a single gene linked ... School of Medicine in St. Louis analyzed the DNA ... failure, and identified 129 variants in four genes that ... 1,117 whites with heart failure and 625 healthy whites ...
(Date:12/14/2009)... from common CT procedures vary widely and are higher than generally ... new study led by University of California, San Francisco (UCSF) ... ... December 14, 2009 -- Radiation doses from common CT procedures vary ... risk for cancer, according to a new study led by University ...
(Date:12/14/2009)... Calif., Dec. 14 Grubb & Ellis Healthcare REIT ... authorized a daily distribution to stockholders of record as of ... commencing on Jan. 1, 2010 and ending on Feb. 28, ... days in the calendar year and will be equal to ... price of $10.00 per share. These distributions will be ...
(Date:12/14/2009)... benefited men whose disease had been treated, hadn,t spread, ... Exercise appears to reduce the risk of death in ... which began in January 1986, included 668 men who,d ... III colon cancer that had not spread (nonmetastatic cancer). ... asked them about any new cancer and disease diagnoses, ...
(Date:12/14/2009)... San Diego School of Medicine and Osaka University in ... liver damage, including inflammation, fibrosis and cancer. The findings ... TAK1, works could lead to new insights into the ... appears to be a master regulator of liver function," ... Dean of the UC San Diego School of Medicine. ...
Breaking Medicine News(10 mins):Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 2Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 3Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 4Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 5Health News:Grubb & Ellis Healthcare REIT II Declares Initial Distribution 2Health News:Grubb & Ellis Healthcare REIT II Declares Initial Distribution 3Health News:Physical Activity May Prolong Survival After Colon Cancer 2Health News:Scientists uncover protective mechanism against liver cancer 2
... Nonprofit Organization, Carolyn,s Compassionate Children gives cancer, ... hope of attending college, BOSTON, June 7 ... senior and cancer survivor Leanna,Elizalde with a $2,500 ... High School,s graduation ceremony Saturday. Alex Oden, 20, ...
... to Acquire, Instantaneous, Non-Stitched Full-Volume Images of the Heart in ... ... TORONTO, June 7 Siemens Healthcare, (http://www.usa.siemens.com/healthcare ) unveils the ... to acquire,non-stitched, real-time full-volume 3D images of the heart in one ...
... glucose levels is key for most diabetics , , FRIDAY, June ... of aggressively lowering blood sugar in people with type 2 ... a 21 percent reduced risk for kidney disease, ... risk of death. , However, the first study found no ...
... Over time, players less able to transfer weight on shots, so ... News) -- If you walk rather than ride a cart when ... and maybe more strokes to your score, a new report suggests. ... change for the worse, causing the player to hit the ball ...
... and Research Assistant Professor Hitoshi Inada (National Institute for ... receptor, PKD1L3-PKD2L1 channel complex, could be activated by acid ... acid stimulus. They call this new type of response ... finding in an international journal, EMBO reports, on June ...
... CRGN ) announced today that Dr. Timothy Shannon, President ... Needham &,Company Biotechnology and Medical Technology Conference on Wednesday, ... is being held at the,New York Palace Hotel in ... of the presentation will be available from the,Investor Relations ...
Other Medicine News:Health News:Nonprofit Organization Dedicated to Helping Young Adult Cancer Survivors Raises $4500 for Leanna Elizalde 2Health News:Siemens' New Ultrasound Platform Revolutionizes the Paradigm of Echocardiography 2Health News:Siemens' New Ultrasound Platform Revolutionizes the Paradigm of Echocardiography 3Health News:Studies Differ on Benefits of Aggressive Blood Sugar Control 2Health News:Studies Differ on Benefits of Aggressive Blood Sugar Control 3Health News:Studies Differ on Benefits of Aggressive Blood Sugar Control 4Health News:Walking Golf Course Affects Swing, Performance 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: